ArticleEuropean heart journal2017
Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.
Article in European heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Prognostic Impact ofJournal of the American Heart Association · 2024Article
- Determining cardiovascular risk in patients with unattributed chest pain in UK primary care: an electronic health record study.European journal of preventive cardiology · 2023Article
- Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review.Journal of clinical medicine · 2023Review
- Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.Current cardiology reports · 2022Review
- Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.Frontiers in cardiovascular medicine · 2022Review
- Drug-Drug-Gene Interactions in Cardiovascular Medicine.Pharmacogenomics and personalized medicine · 2022Review
- Systems biology in cardiovascular disease: a multiomics approach.Nature reviews. Cardiology · 2021Review
- Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients.Aging · 2021Article
- 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y1European cardiology · 2021Review
- Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome.CJC open · 2020Review
- Article
- Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.Therapeutic advances in drug safety · 2020Review
- Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis.BMC medicine · 2019Article
- Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.European heart journal · 2019Article
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.Circulation · 2019Review
- In Aptamers They Trust: The Caveats of the SOMAscan Biomarker Discovery Platform from SomaLogic.Circulation · 2018Article
- Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis.Journal of thrombosis and thrombolysis · 2018Article
- Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.European heart journal · 2018Review
- Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records.PloS one · 2018Article
- Challenges for learning health systems in the NHS. Case study: electronic health records in cardiology.Future healthcare journal · 2017Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
Aims: The aim of this study is to develop models to aid the decision to prolong dual antiplatelet therapy (DAPT) that requires balancing an individual patient's potential benefits and harms. Methods and results: Using population-based electronic health records (EHRs) (CALIBER, England, 2000-10), of patients evaluated 1 year after acute myocardial infarction (MI), we developed (n = 12 694 patients) and validated (n = 5613) prognostic models for cardiovascular (cardiovascular death, MI or stroke) events and three different bleeding endpoints. We applied trial effect estimates to determine potential benefits and harms of DAPT and the net clinical benefit of individuals. Prognostic models for cardiovascular events (c-index: 0.75 (95% CI: 0.74, 0.77)) and bleeding (c index 0.72 (95% CI: 0.67, 0.77)) were well calibrated: 3-year risk of cardiovascular events was 16.5% overall (5.2% in the lowest- and 46.7% in the highest-risk individuals), while for major bleeding, it was 1.7% (0.3% in the lowest- and 5.4% in the highest-risk patients). For every 10 000 patients treated per year, we estimated 249 (95% CI: 228, 269) cardiovascular events prevented and 134 (95% CI: 87, 181) major bleeding events caused in the highest-risk patients, and 28 (95% CI: 19, 37) cardiovascular events prevented and 9 (95% CI: 0, 20) major bleeding events caused in the lowest-risk patients. There was a net clinical benefit of prolonged DAPT in 63-99% patients depending on how benefits and harms were weighted. Conclusion: Prognostic models for cardiovascular events and bleeding using population-based EHRs may help to personalise decisions for prolonged DAPT 1-year following acute MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.